Business Wire

Scoring Big With Fans: Balchem Spotlights the Power of Vitamin K2 at FC Bayern Women’s Season Opener

18.9.2025 15:33:00 EEST | Business Wire | Press release

Share

Balchem, a leading global manufacturer of specialty ingredients for human nutrition and health – and official partner of FC Bayern (FCB) Women’s football team - has launched its first ever direct-to-consumer initiative, showcasing the power of vitamin K2 to FCB fans. The company promoted its K2VITAL™ brand with an exhibition stand at the Allianz Arena in Munich, during the opening game of the Bundesliga (German football league) on 6 September. This initiative is part of Balchem’s latest marketing strategy, which aims to raise consumer awareness of the health benefits vitamin K2 has to offer, bridging the gap between B2B and B2C markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918950889/en/

Balchem Spotlights The Power of Vitamin K2 at FC Bayern Women’s Season Opener

Co-Branded K2 Health Vitamins Hit the Pitch

The opening event of the season provided a unique platform for Balchem to promote K2VITAL™, a patented, typically 99.7% all-trans K2 MK-7 supplement ingredient, to 57,762 football fans in attendance – a new German record. The company spotlighted co-branded products of its customer, Natsana, within the Natural Elements® brand portfolio. As part of the pre-match celebrations, visitors to the booth were encouraged to learn more about the health benefits of K2 from Balchem’s experts with a digital quiz and a cornhole game for the chance to win FCB Women co-branded merchandise. Also highlighted at the booth was a dedicated K2VITAL™ promotion page, offering fans a discount code and the chance to explore the co-branded Natural Elements® product range – including liquid drops, capsules and solutions that combine K2 with vitamin D for bone health support.

When we initiated the partnership with FC Bayern Women, our goal was to educate consumers about vitamin K2 and reinforce the high-quality standards embodied in our K2VITAL™. The team proved to be the perfect partner – acting as outstanding ambassadors of health with over a billion fans worldwide,” comments Dominik Mattern, VP Science, Business Development and Marketing, Balchem Human Nutrition and Health. “Now, we’re taking the next step by hosting our first-ever direct-to-consumer event and harnessing the value of our branded ingredients to drive differentiation. We are so glad to be able to integrate in this first experience a collaboration with our partner Natsana, creating a mutual opportunity for growth.”

Women’s sports are gaining popularity, especially football, with a rapidly growing global fanbase. Balchem’s partnership with FC Bayern Munich gave us the perfect opportunity to showcase the co-branded products range to a large, engaged audience,” concludes Mattern. “Featuring a trusted branded ingredient like K2VITAL™ not only strengthens confidence, but also provides a direct path for consumers to purchase our customers’ products - demonstrating how supplier-brand partnerships can deliver tangible business results.

For more information about Balchem and its brand K2VITAL™, visit: https://balchem.com/hnh/mn/

Notes to Editors:

About Balchem Corporation

Balchem Corporation develops, manufactures, and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health; Animal Nutrition & Health; and Specialty Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market.

About K2VITAL™

K2VITAL™ is patented, typically 99.7% all-trans K2 MK-7. Identical to the K2 molecule found in nature, all-trans MK-7 is the biologically active form of vitamin K2, a fat-soluble vital vitamin that supports calcium metabolism. Vitamin K2 activates vitamin K-dependent proteins, which help direct calcium away from the arteries and deposit it into the bone, supporting bone and heart. K2VITAL™ offers uncompromising quality and stability, providing the maximum benefits of vitamin K2.

More information at:

https://balchem.com/human-nutrition-health/

Follow on LinkedIn:

https://www.linkedin.com/company/balchemhumannutritionandhealth/

Follow on Facebook:

https://www.facebook.com/BalchemHNH

View source version on businesswire.com: https://www.businesswire.com/news/home/20250918950889/en/

Contacts

For further details, contact:

Matilde Martinuzzi
Senior PR Account Executive
BDB Global
matilde.martinuzzi@bdb.co.uk

Bettina Bendig
Director Marketing Consumer Strategy & B2B2C Growth
Balchem Human Nutrition and Health
Bettina.bendig@balchem.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Only 7% of Companies Achieve Full Compliance as Global Expansion Increases Legal Complexity11.5.2026 16:00:00 EEST | Press release

As businesses accelerate their global expansion in 2026, compliance fails to keep pace. In fact, only 7% of organizations report full compliance across their global entities, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC surveyed 350 general counsel (GCs) and senior legal professionals across Europe, North America, and Asia Pacific to examine how their teams navigate international expansion, regulatory pressure, and the increasing adoption of artificial intelligence (AI).¹ The findings appear in CSC’s latest report, General Counsel Barometer 2026: From Complexity to Control. Most organizations report partial compliance, with over half (53%) estimating they are 50–75% compliant, and a further 35% placing themselves between 76%–99%. This leaves just 7% of organizations reporting full compliance across all global entities. GCs also report low confidence in addressing ongoing demands amid global expansion. More than tw

IFF Opens Vanilla Innovation Center in Madagascar11.5.2026 15:15:00 EEST | Press release

IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health & bioscience—today announced the opening of its Vanilla Innovation Center in Madagascar, reinforcing vanilla as a strategic and priority tonality for IFF and strengthening its ability to innovate at origin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260508110162/en/ IFF's Vanilla Innovation Center in Madagascar “The opening of the center marks an important step in how we approach vanilla innovation,” said Adam Jańczuk, Ph.D., senior vice president, research, creation and design, Taste, IFF. “By strengthening our presence at origin, we connect science, creativity and sustainability more closely, responding to climate changes, safeguarding quality and creating value across the supply chain.” Located in Toamasina, Madagascar’s principal seaport, near vanilla growing areas and post‑harvest processing activities, the 650‑square‑meter center bring

ARIS Recognised as a Leader in Gartner ® Magic Quadrant™ for Process Intelligence Platforms, Believes This Reinforces Its Role in Enabling Enterprise AI at Scale11.5.2026 15:00:00 EEST | Press release

ARIS, the process context foundation platform for enterprise AI deployment, today announced its recognition as a Leader in the Gartner® Magic Quadrant™ for Process Intelligence Platforms. This is the fourth consecutive year that ARIS has been recognized as a Leader in the report and the company believes it underscores a continued commitment to innovation and growth as enterprises focus on turning AI ambition into measurable business outcomes. While technology has advanced rapidly, companies are struggling to operationalise AI across complex operating models. ARIS sees this recognition by Gartner as a reflection of its strength in delivering a single unified platform for process intelligence, providing the context layer on which G2000 organisations can successfully deploy and scale agentic AI. “AI is moving from experimentation to execution – but many enterprises are finding it difficult to scale,” said Guillaume Bacuvier, CEO of ARIS. “The reason is simple: AI lacks the context it need

Logistics Reply Named a Visionary in 2026 Gartner® Magic Quadrant™ for Warehouse Management Systems and Ranks #2 for Level 2 and #3 for Level 3 Operations Use Cases in Gartner® Critical Capabilities Report11.5.2026 15:00:00 EEST | Press release

Logistics Reply, the Reply Group company specializing in innovative solutions for supply chain execution, is proud to announce its recognition as a Visionary in the Gartner® Magic Quadrant™ for Warehouse Management Systems for the seventh consecutive year, as its global team of warehouse technology professionals continues to drive innovation that puts customers first. Additionally, Logistics Reply for its LEA Reply™ WMS is recognized in the 2026 Gartner® Critical Capabilities for Warehouse Management Systems report where it ranked #2 for Level 2 Warehouse Operations and #3 for Level 3 Warehouse Operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511344452/en/ We believe these important recognitions underscore Logistics Reply's commitment to delivering intelligent, flexible and scalable warehouse execution solutions for enterprise customers around the world. For us, our placement in the Visionaries Quadrant reflects

HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors11.5.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De Novo request to the U.S. Food and Drug Administration seeking authorization to expand the use of its Edison® Histotripsy System to include the destruction of kidney (renal) tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511268688/en/ HistoSonics Edison® Histotripsy System This milestone marks a significant step forward in the company’s mission to transform the treatment of solid tumors with a completely non-invasive technology that harnesses focused ultrasound to mechanically liquefy and destroy targeted tissue, reducing the risk of many complications and side effects associated with surgery, radiation, and other common therapies. “This submission is an important milestone in expanding histotripsy beyond the liver and into the kidney, an area where patients and physicians are s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye